10-Q 1 tv477964_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

| þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended | September 30, 2017

or

| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from | _____________________ to ______________________

Commission File Number: | 001-37776

SHINECO, INC.
(Exact name of registrant as specified in its charter)

Delaware | 52-2175898
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)
Room 1001, Building T5, DaZu Square, Daxing District, Beijing People’s Republic of China | 100176
(Address of principal executive offices) | (Zip Code)

(+86) 10-87227366
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Yes x No ¨

and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ¨ | Accelerated filer | ¨
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | x
|  | Emerging growth company | x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

As of November 13, 2017, the registrant had 21,034,072 shares of common stock outstanding.

TABLE OF CONTENTS

| Page Number
PART I. FINANCIAL INFORMATION | F-1
Item 1. | Financial Statements | F-1
| Condensed Consolidated Balance Sheets (unaudited) | F-1
| Condensed Consolidated Statements of Income and Comprehensive Income (Loss) (unaudited) | F-2
| Condensed Consolidated Statements of Cash Flows (unaudited) | F-3
| Notes to the Condensed Consolidated Financial Statements (unaudited) | F-4
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 4
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 16
Item 4. | Controls and Procedures | 16
PART II. OTHER INFORMATION | 17
Item 1. | Legal Proceedings | 17
Item 1A. | Risk Factors | 17
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 17
Item 3. | Defaults Upon Senior Securities | 17
Item 4. | Mine Safety Disclosures | 17
Item 5. | Other Information | 17
Item 6. | Exhibits | 18
SIGNATURES | 19

| 2 |

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains certain statements of a forward-looking nature. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “should,” “will,” “could” and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements.

Examples of forward-looking statements include:

| • | the timing of the development of future products;

| • | projections of revenue, earnings, capital structure and other financial items;

| • | statements of our plans and objectives, including those that relate to our proposed expansions and the effect such expansions may have on our revenues;

| • | statements regarding the capabilities of our business operations;

| • | statements of expected future economic performance;

| • | statements regarding competition in our market; and

| • | assumptions underlying statements regarding us or our business.

The ultimate correctness of these forward-looking statements depends upon a number of known and unknown risks and events. We discuss our known material risks under the heading “Risk Factors” in our Registration Statement on Form S-1. Many factors could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements.

The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Nonetheless, the Company reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this Report. No such update shall be deemed to indicate that other statements not addressed by such update is incorrect or create an obligation to provide any other updates.

| 3 |

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SHINECO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS |  |  |  |  |  |
|  | September 30, |  |  | June 30, |
|  | 2017 |  |  | 2017 |
|  | (Unaudited) |  |  |  |
CURRENT ASSETS: |  |  |  |  |  |  |  |
Cash |  | $ | 27,728,940 |  |  | $ | 23,154,551 |
Accounts receivable, net |  |  | 13,152,878 |  |  |  | 14,480,004 |
Due from related parties |  |  | 454,765 |  |  |  | 448,833 |
Inventories |  |  | 2,287,546 |  |  |  | 2,346,273 |
Advances to suppliers, net |  |  | 2,765,611 |  |  |  | 2,396,123 |
Loans to third parties, net |  |  | - |  |  |  | 830,090 |
Other receivables, net |  |  | 561,838 |  |  |  | 535,700 |
Short-term deposit |  |  | 167,867 |  |  |  | 158,894 |
Prepaid expenses |  |  | 250,730 |  |  |  | 375,459 |
TOTAL CURRENT ASSETS |  |  | 47,370,175 |  |  |  | 44,725,927 |
Property and equipment at cost, net of accumulated depreciation and amortization |  |  | 10,380,424 |  |  |  | 10,320,396 |
Land use right, net of accumulated amortization |  |  | 1,363,063 |  |  |  | 1,346,631 |
Investments |  |  | 5,945,030 |  |  |  | 5,695,080 |
Deposit for business acquisition |  |  | 2,103,710 |  |  |  | 2,065,686 |
Long-term deposit and other noncurrent assets |  |  | 113,650 |  |  |  | 112,883 |
Prepaid leases |  |  | 3,735,559 |  |  |  | 3,784,533 |
Deferred tax assets |  |  | 264,677 |  |  |  | 233,834 |
TOTAL ASSETS |  | $ | 71,276,288 |  |  | $ | 68,284,970 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |
CURRENT LIABILITIES: |  |  |  |  |  |  |  |
Short-term loans |  | $ | 2,253,975 |  |  | $ | 2,663,628 |
Accounts payable |  |  | 146,027 |  |  |  | 158,068 |
Advances from customers |  |  | 657,701 |  |  |  | 5,439 |
Due to related parties |  |  | 305,191 |  |  |  | 257,880 |
Other payables and accrued expenses |  |  | 263,596 |  |  |  | 337,107 |
Taxes payable |  |  | 1,667,745 |  |  |  | 1,608,926 |
TOTAL LIABILITIES |  |  | 5,294,235 |  |  |  | 5,031,048 |
Commitments and contingencies |  |  | - |  |  |  | - |
EQUITY: |  |  |  |  |  |  |  |
Common stock; par value $0.001, 100,000,000 shares authorized; |  |  |  |  |  |  |  |
21,034,072 and 21,034,072 shares issued and outstanding at September 30, 2017 and June 30, 2017 |  |  | 21,034 |  |  |  | 21,034 |
Additional paid-in capital |  |  | 22,737,302 |  |  |  | 22,737,302 |
Statutory reserve |  |  | 3,570,859 |  |  |  | 3,484,449 |
Retained earnings |  |  | 40,234,223 |  |  |  | 39,064,743 |
Accumulated other comprehensive loss |  |  | (1,691,594 | ) |  |  | (3,140,982 | )
Total Stockholders' equity of Shineco, Inc. |  |  | 64,871,824 |  |  |  | 62,166,546 |
Non-controlling interest |  |  | 1,110,229 |  |  |  | 1,087,376 |
TOTAL EQUITY |  |  | 65,982,053 |  |  |  | 63,253,922 |
TOTAL LIABILITIES AND EQUITY |  | $ | 71,276,288 |  |  | $ | 68,284,970 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

| F-1 |

SHINECO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

|  | For the Three Months Ended September 30, |
|  | 2017 |  |  | 2016 |
REVENUE |  | $ | 7,809,494 |  |  | $ | 6,366,664 |
COST OF REVENUE |  |  |  |  |  |  |  |
Cost of product and services |  |  | 5,705,511 |  |  |  | 4,436,172 |
Business and sales related tax |  |  | 15,613 |  |  |  | 15,545 |
Total cost of revenue |  |  | 5,721,124 |  |  |  | 4,451,717 |
GROSS PROFIT |  |  | 2,088,370 |  |  |  | 1,914,947 |
OPERATING EXPENSES |  |  |  |  |  |  |  |
General and administrative expenses |  |  | 835,551 |  |  |  | 473,764 |
Selling expenses |  |  | 294,936 |  |  |  | 380,318 |
Total operating expenses |  |  | 1,130,487 |  |  |  | 854,082 |
INCOME FROM OPERATIONS |  |  | 957,883 |  |  |  | 1,060,865 |
OTHER INCOME |  |  |  |  |  |  |  |
Income from equity method investments |  |  | 148,458 |  |  |  | 161,182 |
Purchase rebate income |  |  | 368,803 |  |  |  | 239,990 |
Other income |  |  | 85,619 |  |  |  | 85,901 |
Interest income (expense), net |  |  | (19,185 | ) |  |  | 32,753 |
Total other income |  |  | 583,695 |  |  |  | 519,826 |
INCOME BEFORE PROVISION FOR INCOME TAXES |  |  | 1,541,578 |  |  |  | 1,580,691 |
PROVISION FOR INCOME TAXES |  |  | 282,857 |  |  |  | 201,636 |
NET INCOME |  |  | 1,258,721 |  |  |  | 1,379,055 |
Less: net income attributable to non-controlling interest |  |  | 2,831 |  |  |  | 30,348 |
NET INCOME ATTRIBUTABLE TO SHINECO, INC. |  | $ | 1,255,890 |  |  | $ | 1,348,707 |
COMPREHENSIVE INCOME |  |  |  |  |  |  |  |
Net income |  | $ | 1,258,721 |  |  | $ | 1,379,055 |
Other comprehensive income (loss): foreign currency translation gain (loss) |  |  | 1,469,410 |  |  |  | (196,681 | )
Total comprehensive income |  |  | 2,728,131 |  |  |  | 1,182,374 |
Less: comprehensive income attributable to non-controlling interest |  |  | 22,853 |  |  |  | 26,626 |
COMPREHENSIVE INCOME ATTRIBUTABLE TO SHINECO, INC. |  | $ | 2,705,278 |  |  | $ | 1,155,748 |
Weighted average number of shares basic and diluted |  |  | 21,034,072 |  |  |  | 19,376,747 |
Basic and diluted earnings per common share |  | $ | 0.06 |  |  | $ | 0.07 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

| F-2 |

SHINECO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

|  | For the Three Months Ended September 30, |
|  | 2017 |  |  | 2016 |
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |
Net income |  | $ | 1,258,721 |  |  | $ | 1,379,055 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 146,627 |  |  |  | 157,010 |
(Recovery of) provision for doubtful accounts |  |  | (109,121 | ) |  |  | 103,880 |
Increase (decrease) in inventory reserve |  |  | 93,453 |  |  |  | (24,836 | )
Deferred tax benefit |  |  | (26,479 | ) |  |  | (3,883 | )
Income from equity method investments |  |  | (148,458 | ) |  |  | (161,182 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 1,621,378 |  |  |  | (1,607,621 | )
Advances to suppliers |  |  | (336,622 | ) |  |  | (383,769 | )
Inventories |  |  | 8,229 |  |  |  | 573,591 |
Other receivables |  |  | 345,841 |  |  |  | (204,953 | )
Prepaid expense and other assets |  |  | 124,496 |  |  |  | 5,034 |
Due from related parties |  |  | 2,324 |  |  |  | 280,988 |
Prepaid leases |  |  | 118,365 |  |  |  | 119,398 |
Accounts payable |  |  | (14,916 | ) |  |  | 45,871 |
Advances from customers |  |  | 650,665 |  |  |  | 31,181 |
Other payables |  |  | (79,636 | ) |  |  | 143,166 |
Taxes payable |  |  | 30,257 |  |  |  | (37,421 | )
NET CASH PROVIDED BY OPERATING ACTIVITIES |  |  | 3,685,124 |  |  |  | 415,509 |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |
Acquisitions of property and equipment |  |  | (7,335 | ) |  |  | (22,131 | )
Loan advances to third parties |  |  | - |  |  |  | (108,648 | )
Repayments of loans from third parties |  |  | 830,717 |  |  |  | - |
Repayments of loans from related parties |  |  | - |  |  |  | 130,495 |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES |  |  | 823,382 |  |  |  | (284 | )
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |
Proceeds from short-term loans |  |  | 299,840 |  |  |  | 781,469 |
Repayment of short-term loans |  |  | (757,470 | ) |  |  | (786,719 | )
Stock issuance cost payable |  |  | - |  |  |  | 843,844 |
Proceeds from initial public offering, net of offering costs |  |  | - |  |  |  | 5,394,549 |
Proceeds from advances from related parties |  |  | 42,466 |  |  |  | 97,413 |
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES |  |  | (415,164 | ) |  |  | 6,330,556 |
EFFECT OF EXCHANGE RATE CHANGE ON CASH |  |  | 481,047 |  |  |  | (85,654 | )
NET INCREASE IN CASH |  |  | 4,574,389 |  |  |  | 6,660,127 |
CASH - Beginning of the Period |  |  | 23,154,551 |  |  |  | 22,009,374 |
CASH - End of the Period |  | $ | 27,728,940 |  |  | $ | 28,669,501 |
SUPPLEMENTAL CASH FLOW DISCLOSURES: |  |  |  |  |  |  |  |
Cash paid for income tax |  | $ | 273,474 |  |  | $ | 65,436 |
Cash paid for interest |  | $ | 36,208 |  |  | $ | 39,303 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

| F-3 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Shineco, Inc. (“Shineco” or the “Company”) was incorporated in the State of Delaware on August 20, 1997. The Company is a holding company whose primary purpose is to develop business opportunities in the People’s Republic of China (“PRC” or “China”).

On December 30, 2004, the Company acquired all of the issued and outstanding shares of Beijing Tenet-Jove Technological Development Co., Ltd. (“Tenet-Jove”), a PRC company, in exchange for restricted shares of the Company’s common stock, and the sole operating business of the Company became that of its subsidiary, Tenet-Jove. Tenet-Jove was incorporated on December 15, 2003 under the laws of China. Consequently, Tenet-Jove became a 100% owned subsidiary of Shineco and was officially granted the status of a Wholly Foreign-Owned Entity (“WFOE”) by Chinese authorities on July 14, 2006. This transaction was accounted for as a recapitalization. Tenet-Jove owns 90% interest of Tianjin Tenet Huatai Technological Development Co., Ltd. (“Tenet Huatai”).

On December 31, 2008, June 11, 2011 and May 24, 2012, Tenet-Jove entered into a series of contractual agreements with Ankang Longevity Pharmaceutical (Group) Co., Ltd. (“Ankang Longevity Group”), Yantai Zhisheng International Freight Forwarding Co., Ltd. (“Zhisheng Freight”), Yantai Zhisheng International Trade Co., Ltd. (“Zhisheng Trade”), Yantai Mouping District Zhisheng Agricultural Produce Cooperative (“Zhisheng Agricultural”) and Qingdao Zhihesheng Agricultural Produce Services., Ltd. (“Qingdao Zhihesheng”). On February 24, 2014, Tenet-Jove entered into the same series of contractual agreements with Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. (“Zhisheng Bio-Tech”), which was incorporated in 2014. Zhisheng Bio-Tech, Zhisheng Freight, Zhisheng Trade, Zhisheng Agricultural, and Qingdao Zhihesheng are collectively referred to herein as “Zhisheng Group”. The contractual agreements include an Executive Business Cooperation Agreement, Timely Reporting Agreement, Equity Interest Pledge Agreement and Executive Option Agreement.

On April 19, 2017, Tenet-Jove established Xinjiang Tiankunrunze Biological Engineering Co., Ltd. (“Tiankunrunze”) and owned 65% interest of Tiankunrunze. On April 28, 2017, Tiankunrunze established Xinjiang Tianzhuo Technology Development Co., Ltd. (“Tianzhuo”) with registered capital of RMB 10.0 million ($1,450,233). On May 22, 2017, Tiankunrunze established Xinjiang Tianhuihechuang Agriculture Development Co., Ltd. (“Tianhuihechuang”) with registered capital of RMB 10.0 million ($1,452,294). On May 23, 2017, Tiankunrunze established Xinjiang Tianxintongye Biotechnology Development Co., Ltd. (“Tianxintongye”) with registered capital of RMB 10.0 million ($1,451,615). Tianzhuo, Tianhuihechuang and Tianxintongye became subsidiaries of Tenet-Jove.

On May 2, 2017, the Company and its subsidiary Tiankunrunze have entered into a Strategic Cooperation Agreement with Beijing Zhongke Biorefinery Engineering Technology Co., Ltd. (“Biorefinery”), a leading high-tech biomass refining company financially backed by the Chinese Academy of Sciences Institute of Process Engineering, to establish the Institute of Chinese Apocynum Industrial Technology Research (“ICAITR”). Pursuant to the Strategic Cooperation Agreement the three parties agreed to establish the ICAITR and each will own 45%, 35% and 20% of the equity interests of ICAITR, respectively. Shineco and Tiankunrunze will invest RMB 5.0 million ($737,745) as the registered capital, and Biorefinery will invest technology such as the patent for “Steam Explosion Degumming” as well as other resources.

Pursuant to the above agreements, Tenet-Jove has the exclusive right to provide to Zhisheng Group and Ankang Longevity Group consulting services related to their business operations and management. All the above contractual agreements obligate Tenet-Jove to absorb a majority of the risk of loss from the Zhisheng Group and Ankang Longevity Group’s activities and entitle Tenet-Jove to receive a majority of their residual returns. In essence, Tenet-Jove has gained effective control over the Zhisheng Group and Ankang Longevity Group. Therefore, the Zhisheng Group and Ankang Longevity Group are treated as Variable Interest Entities (“VIEs”) under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 “Consolidation”. Accordingly, the accounts of these entities are consolidated with those of Tenet-Jove.

| F-4 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Since Shineco is effectively controlled by the majority shareholders of the Zhisheng Group and Ankang Longevity Group, Shineco owns 100% of Tenet-Jove. Accordingly, Shineco, Tenet-Jove, and its VIEs, the Zhisheng Group and Ankang Longevity Group are effectively controlled by the same majority shareholders. Therefore, Shineco, Tenet-Jove and its VIEs are considered under common control. The consolidation of Tenet-Jove and its VIEs into Shineco has been accounted for at historical cost and prepared on the basis as if the aforementioned exclusive contractual agreements between Tenet-Jove and its VIEs had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements.

The Company, its subsidiaries, its VIEs and its VIEs’ subsidiaries (collectively the “Group”) operate three main business segments: 1) Tenet-Jove is engaged in manufacturing and selling of Bluish Dogbane and related products, also known in Chinese as “Luobuma”, including therapeutic clothing and textile products made from Luobuma; 2) Zhisheng Group is engaged in the business of planting, processing and distributing of green agricultural produce as well as providing domestic and international logistic services for agricultural products (“Agricultural Products”); and, 3) Ankang Longevity Group manufactures traditional Chinese medicinal herbal products as well as other retail pharmaceutical products. These different business activities and products can potentially be integrated and benefit from one and other.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information pursuant to the rules of the SEC and have been consistently applied. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results of a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2017, which was filed on October 13, 2017.

The unaudited condensed consolidated financial statements of the Company reflect the principal activities of the Company, its subsidiaries, its VIEs and its VIEs’ subsidiaries. The non-controlling interest represents the minority shareholders’ interest in the Company’s majority owned subsidiaries. All intercompany transactions have been eliminated.

Consolidation of Variable Interest Entities

VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs and their subsidiaries with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes.

The carrying amount of the VIEs and their subsidiaries’ consolidated assets and liabilities are as follows:

|  | September 30, 2017 |  |  | June 30, 2017 |
Current assets |  | $ | 43,596,320 |  |  | $ | 40,584,817 |
Plant and equipment, net |  |  | 9,003,058 |  |  |  | 8,958,282 |
Other noncurrent assets |  |  | 10,926,075 |  |  |  | 10,707,344 |
Total assets |  |  | 63,525,453 |  |  |  | 60,250,443 |
Total liabilities |  |  | (5,016,236 | ) |  |  | (4,662,387 | )
Net assets |  | $ | 58,509,217 |  |  | $ | 55,588,056 |

Non-controlling Interests

US GAAP requires that non-controlling interests in subsidiaries and affiliates be reported in the equity section of a company’s balance sheet. In addition, the amounts attributable to the net income of these entities are reported separately in the unaudited condensed consolidated statements of income and comprehensive income.

| F-5 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Risks and Uncertainties

The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among other factors, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC, and by changes in governmental policies or interpretations with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations, changes could effect..

Members of the current management team own controlling interests in the Company and are also the owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenue and expenses during the reporting periods. Significant estimates required to be made by management include, but are not limited to, useful lives of property, plant, and equipment, and intangible assets, the recoverability of long-lived assets and the valuation of accounts receivable, accrued expenses, taxes payable and inventory reserves. Actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue from sales of Luobuma products, Chinese medicinal herbal products and agricultural products, as well as providing logistic services and other processing services to external customers. The Company recognizes revenue when all of the following have occurred: (i) there is persuasive evidence of an arrangement with a customer; (ii) delivery has occurred or services have been rendered; (iii) the sales price is fixed or determinable; and (iv) the Company’s collection of such fees is reasonably assured. These criteria, as related to the Company’s revenue, are considered to have been met as follows:

Sales of products: The Company recognizes revenue from the sale of products when the goods are delivered and title to the goods passes to the customer provided that there are no uncertainties regarding customer acceptance; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability is deemed probable.

Revenue from the rendering of services: Revenue from international freight forwarding, domestic air and overland freight forwarding services is recognized upon the performance of services as stipulated in the underlying contract or when commodities are being released from the customer’s warehouse; the service price is fixed or determinable; and collectability is deemed probable.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, cash on deposit and other highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less when purchased. The Company maintains cash with various financial institutions mainly in the PRC. Balances in banks in the PRC are uninsured. As of September 30, 2017 and June 30, 2017, the Company had no cash equivalents.

| F-6 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Accounts Receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, the customers’ historical payment history, their current credit-worthiness and current economic trends. As of September 30, 2017 and June 30, 2017, the allowance for doubtful accounts was $17,898 and $48,450, respectively. Accounts are written off against the allowance after efforts at collection prove unsuccessful.

Inventories

Inventories, which are stated at the lower of cost or current market value, consist of raw materials, work-in-progress, and finished goods related to the Company’s products. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. Agricultural products that the Company farms are recorded at cost, which includes direct costs such as seed selection, fertilizer, labor cost and contract fees that are spent in growing agricultural products on the leased farmland, and indirect costs which include amortization of prepayments of farmland leases and farmland development costs. All the costs are accumulated until the time of harvest and then allocated to the harvested crops costs when they are sold. The Company periodically evaluates its inventory and records an inventory reserve for certain inventories that may not be saleable or whose cost exceeds market prices.

Advances to Suppliers

Advances to suppliers consist of payments to suppliers for materials that have not been received. Advances to suppliers are reviewed periodically to determine whether their carrying value has become impaired. As of September 30, 2017 and June 30, 2017, the Company had an allowance for uncollectible advances to suppliers of $29,958 and $17,618, respectively.

Loans to Third Parties

Loans to third parties consist of various cash advances to unrelated companies and individuals, with whom the Company has business relationships. The loans are due within one year with no interest. Loans to third parties are reviewed periodically as to whether their carrying values remain realizable.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for additions, major renewals and betterments are capitalized, and expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is provided on a straight-line basis, less estimated residual value, if any, over an asset’s estimated useful life. Farmland leasehold improvements are amortized over the shorter of lease term or estimated useful lives of the underlying assets. The estimated useful lives of the Company’s property and equipment are as follows:

|  | Estimated useful lives
Buildings |  | 20-50 years
Machinery equipment |  | 5-10 years
Motor vehicles |  | 5-10 years
Office equipment |  | 5-10 years
Farmland leasehold improvements |  | 12-18 years

| F-7 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Land Use Rights

According to the Chinese laws and regulations regarding land use rights, land in urban districts is owned by the State, while land in the rural areas and suburban areas, except otherwise provided for by the State, is collectively owned by individuals designated as resident farmers by the State. In accordance with the legal principle that land ownership is separate from the right to the use of the land, the government grants individuals and companies the rights to use parcels of land for a specified period of time. Land use rights which are usually prepaid, are stated at cost less accumulated amortization. Amortization is provided over the respective useful lives, using the straight-line method. The estimated useful life is 50 years, based on the term of the land use rights.

Long-lived Assets

Finite-lived assets and intangibles are reviewed for impairment testing when circumstances require. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company that are subject to evaluation consist primarily of property, plant and equipment, land use rights, investments and long-term prepaid leases. For the three months ended September 30, 2017 and 2016, the Company did not recognize any impairment of its long-lived assets.

Fair Value of Financial Instruments

The Company follows the provisions of ASC 820, “Fair Value Measurements and Disclosures.” ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying value of financial instruments included in current assets and liabilities approximate their fair values because of the short-term nature of these instruments.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the unaudited condensed consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

The provisions of ASC 740-10-25, “Accounting for Uncertainty in Income Taxes,” prescribe a more-likely-than-not threshold for consolidated financial statement recognition and measurement of a tax position taken (or expected to be taken) in a tax return. This ASC also provides guidance on the recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, and related disclosures. The Company does not have any uncertain tax positions at September 30, 2017 and June 30, 2017. The Company has not provided deferred taxes of undistributed earnings of non-U.S. subsidiaries at September 30, 2017, as it is the Company's policy to indefinitely reinvest these earnings in non-U.S. operations. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested earnings is not practicable.

| F-8 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

The statute of limitations for the Company’s U.S. federal income tax returns and certain state income tax returns remains open for tax years 2007 and after. As of September 30, 2017, the tax years ended June 30, 2012 through June 30, 2017 for the Company’s People’s Republic of China (“PRC”) subsidiaries remain open for statutory examination by PRC tax authorities.

Value Added Tax

Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing finished products or acquiring finished products. The Company records a VAT payable or VAT receivable in the accompanying unaudited condensed consolidated financial statements.

Foreign Currency Translation

The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency of Renminbi (“RMB”), the currency of the PRC.

In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting periods. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive (loss).

The balance sheet amounts, with the exception of equity, at September 30, 2017 and June 30, 2017 were translated at 1 RMB to 0.1503 USD and at 1 RMB to 0.1475 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the three months ended September 30, 2017 and 2016 were at 1 RMB to 0.1499 USD and at 1 RMB to 0.1500 USD, respectively.

Comprehensive Income

Comprehensive income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to USD is reported in other comprehensive income (loss) in the unaudited condensed consolidated statements of income and comprehensive income.

Equity Investment

An investment in which the Company has the ability to exercise significant influence, but does not have a controlling interest, is accounted for using the equity method. Significant influence is generally considered to exist when the Company has an ownership interest in the voting stock between 20% and 50%, and other factors, such as representation on the Board of Directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate.

| F-9 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Earnings per Share

The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There is no anti-dilutive effect for the three months ended September 30, 2017 and 2016.

New Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02 Amendments to the ASC 842 Leases. This update requires a lessee to recognize the assets and liability (the lease liability) arising from operating leases on the balance sheet for the lease term. When measuring assets and liabilities arising from a lease, a lessee (and a lessor) should include payments to be made in optional periods only if the lessee is reasonably certain to exercise an option to extend the lease or not to exercise an option to terminate the lease. Within a twelve months or less lease term, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. If a lessee makes this election, it should recognize lease expense on a straight-line basis over the lease term. In transition, this update will be effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company does not currently expect the adoption of ASU 2016-02 to have a material impact on the Company’s financial statements unless it enters into a new long-term lease.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (ASC 718): Improvements to Employee Share-Based Payment Accounting. The objective is to identity, evaluate, and improve areas of generally accepted accounting principles (GAAP) for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The areas for simplification include the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas apply only to nonpublic entities. For public business entities, the ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. For all other entities, the ASU is effective for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The adoption of ASU 2016-09 did not impact our financial statements.

In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (ASC 606): Identifying Performance Obligations and Licensing. The objective is to clarify the two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for these areas. The ASU affects the guidance in ASU 2014-09, Revenue from Contracts with Customers (ASC 606), which is not yet effective. The effective date and transition requirements for this ASU are the same as the effective date and transition requirements in ASC 606 (and any other Topic amended by ASU 2014-09). ASU 2015-14, Revenue from Contracts with Customers (ASC 606): Deferral of the Effective Date, defers the effective date of ASU 2014-09 by one year. The Company does not expect the adoption of ASU 2016-10 to have a material impact on the Company’s financial statements.

In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (ASC 606): Narrow-Scope Improvements and Practical Expedients. The objective is to address certain issues identified by the FASB-IASB Joint Transition Resource Group for Revenue Recognition. The amendments in this Update affect the guidance in Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606), which is not yet effective. The effective date and transition requirements for the amendments in this Update are the same as the effective date and transition requirements for ASC 606 (and any other Topic amended by Update 2014-09). Accounting Standards Update 2015-14, Revenue from Contracts with Customers (ASC 606): Deferral of the Effective Date, defers the effective date of Update 2014-09 by one year. The Company does not expect the adoption of ASU 2016-12 to have a material impact on the Company’s financial statements.

| F-10 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

In June 2016 the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which eliminates the probable initial recognition threshold for credit losses in current U.S. GAAP, and instead requires an organization to record a current estimate of all expected credit losses over the contractual term for financial assets carried at amortized cost. This is commonly referred to as the current expected credit losses (“CECL”) methodology. Expected credit losses for financial assets held at the reporting date will be measured based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 does not change the existing write-off principle in U.S. GAAP or current nonaccrual practices, nor does it change accounting requirements for loans held for sale or certain other financial assets which are measured at the lower of amortized cost or fair value. As a public business entity that is an SEC filer, ASU 2016-13 becomes effective for the Company on January 1, 2020, although early application is permitted for 2019. The Company is currently evaluating the potential effects on the Company’s financial statements, if any.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to address diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments provide guidance on the following eight specific cash flow issues: (1) Debt Prepayment or Debt Extinguishment Costs; (2) Settlement of Zero-Coupon Debt Instruments or Other Debt Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing; (3) Contingent Consideration Payments Made after a Business Combination; (4) Proceeds from the Settlement of Insurance Claims; (5) Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned; (6) Life Insurance Policies; (7) Distributions Received from Equity Method Investees; (8) Beneficial Interests in Securitization Transactions; and Separately Identifiable Cash Flows and Application of the Predominance Principle. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The amendments should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company does not expect the adoption of ASU 2016-15 to have a material impact on the Company’s financial statements.

In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance will be effective in the first quarterly of 2018 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-18 to have a material impact on the Company’s financial statements.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the definition of a business. The amendments in this ASU is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The amendments are effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. For all other entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. The Company does not believe the adoption of this ASU would have a material effect on the Company’s financial statements.

In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting, which amends the scope of modification accounting for share-based payment arrangements and provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. For all entities, this ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The adoption of this ASU is not expected to have a material effect on the Company’s financial statements.

| F-11 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 3- INVENTORIES

The inventories consist of the following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Raw materials |  | $ | 980,069 |  |  | $ | 1,167,553 |
Work-in-process |  |  | 363,449 |  |  |  | 672,966 |
Finished goods |  |  | 1,893,854 |  |  |  | 1,346,437 |
Less: inventory reserve |  |  | (949,826 | ) |  |  | (840,683 | )
Total |  | $ | 2,287,546 |  |  | $ | 2,346,273 |

Work-in-process includes direct costs such as seed selection, fertilizer, labor cost and subcontractor fees that are spent in growing agricultural products on the leased farmland, and indirect costs which include amortization of the prepayment of the farmland lease fees and farmland development costs. All the costs are accumulated until the time of harvest and then allocated to harvested crop costs when they are sold.

NOTE 4- PROPERTY AND EQUIPMENT, NET

Property and equipment consist of the following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Buildings |  | $ | 10,709,838 |  |  | $ | 10,516,245 |
Building improvements |  |  | 52,750 |  |  |  | 51,797 |
Machinery and equipment |  |  | 484,829 |  |  |  | 474,888 |
Motor vehicles |  |  | 49,547 |  |  |  | 48,651 |
Construction in progress |  |  | 450,795 |  |  |  | 442,646 |
Office equipment |  |  | 162,805 |  |  |  | 153,836 |
Farmland leasehold improvements |  |  | 3,159,917 |  |  |  | 3,102,803 |
|  |  | 15,070,481 |  |  |  | 14,790,866 |
Less: accumulated depreciation and amortization |  |  | (4,690,057 | ) |  |  | (4,470,470 | )
Property, plant and equipment, net |  | $ | 10,380,424 |  |  | $ | 10,320,396 |

Depreciation and amortization expense charged to operations was $136,982 and $147,367 for the three months ended September 30, 2017 and 2016, respectively.

Farmland leasehold improvements consist of following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Blueberry farmland leasehold reconstruction |  | $ | 2,427,589 |  |  | $ | 2,383,711 |
Yew tree planting base reconstruction |  |  | 271,980 |  |  |  | 267,064 |
Greenhouse renovation |  |  | 460,348 |  |  |  | 452,028 |
Total farmland leasehold improvements |  | $ | 3,159,917 |  |  | $ | 3,102,803 |

| F-12 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 5- LAND USE RIGHTS

Land use rights are recognized at cost less accumulated amortization. According to the Chinese laws and regulations regarding land use rights, land in urban districts is owned by the State, while land in the rural areas and suburban areas, except otherwise provided for by the State, is collectively owned by individuals designated as resident farmers by the State. However, in accordance with the legal principle that land ownership is separate from the right to the use of the land, the government grants the user a “land use right” (the “Right”) to use the land. The Company has the Right to use the land for 50 years and amortizes the rights on a straight-line basis over the period of 50 years.

|  | September 30, 2017 |  |  | June 30, 2017 |
Land use rights |  | $ | 1,671,395 |  |  | $ | 1,641,181 |
Less: accumulated amortization |  |  | (308,332 | ) |  |  | (294,550 | )
Land use rights, net |  | $ | 1,363,063 |  |  | $ | 1,346,631 |

For the three months ended September 30, 2017 and 2016, the Company recognized amortization expense of $9,645 and $9,643, respectively.

The estimated future amortization expenses are as follows:

Twelve months ending September 30: |  |  |
2018 |  | $ | 33,428 |
2019 |  |  | 33,428 |
2020 |  |  | 33,428 |
2021 |  |  | 33,428 |
2022 |  |  | 33,428 |
Thereafter |  |  | 1,195,923 |
Total |  | $ | 1,363,063 |

NOTE 6 - INVESTMENTS

Ankang Longevity Group entered into two equity investment agreements with Shaanxi Pharmaceutical Group Pai’ang Medicine Co. Ltd. (“Shaanxi Pharmaceutical Group”), a Chinese state-owned pharmaceutical enterprise to invest a total of RMB 6.8 million (approximately $1.0 million) to form a joint venture pharmacy retail company called Shaanxi Pharmaceutical Sunsimiao Drugstores Ankang Retail Chain Co., Ltd. (“Sunsimiao Drugstores”), and a joint venture pharmaceutical wholesale distribution company named Shaanxi Pharmaceutical Holding Group Longevity Pharmacy Co., Ltd. (“Shaanxi Longevity Pharmacy”). Ankang Longevity Group obtained 49% interest in each of these two new joint venture companies. These two joint ventures were formed as new business entities to collaborate with Shaanxi Pharmaceutical Group to expand sales to regional hospitals and clinics and to establish the presence of retail pharmacies under the Brand name “Sunsimiao”. The investments are accounted for using the equity method because Ankang Longevity Group has significant influence, but no control of these two entities. Ankang Longevity Group recorded income of $148,458 and $161,182 for the three months ended September 30, 2017 and 2016, respectively, from the investments, which was included in “Income from equity method investments” in the unaudited condensed consolidated statements of income and comprehensive income.

Ankang Longevity Group entered into a supplemental agreement with Shaanxi Pharmaceutical Group. According to the supplemental agreement, the new joint-venture companies established by Shaanxi Pharmaceutical Group and Ankang Longevity Group are required to exclusively purchase certain raw materials and drug products from Shaanxi Pharmaceutical Group. In return, Shaanxi Pharmaceutical Group has agreed to compensate Ankang Longevity Group with a purchase rebate of 7% of the total purchases made from Shaanxi Pharmaceutical Group. For the three months ended September 30, 2017 and 2016, a total of $368,803 and $239,990 was recognized by Ankang Longevity Group from this supplemental agreement in addition to its 49% share of the income from the joint ventures, respectively.

| F-13 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

On October 21, 2013, the Company, through its controlled subsidiaries, Zhisheng Freight and Zhisheng Agricultural, entered into an agreement with an unrelated third party, Zhejiang Zhen’Ai Network Warehousing Services Co., Ltd. (“Zhen’Ai Network”), and invested RMB 14.5 million (approximately $2.2 million) into Tiancang Systematic Warehousing project (“Tiancang Project”) operated by Zhen’Ai Network. The Tiancang Project is an online platform established to provide comprehensive warehousing and logistic solutions to companies involved in E-commerce. The Company is entitled to 29% of Tiancang Project’s after-tax net income annually, less 30% statutory reserve and 10% employee welfare fund. When the amount of the accumulated statutory reserve reaches 30% of the total investment for the Tiancang Project, no additional appropriation of the statutory reserve is required. For the three months ended September 30, 2017 and 2016, the Company did not record investment income from this investment.

On November 21, 2016, the Company (the “Investor”) entered into an agreement with Original Lab Inc., a California corporation (the “Investee”), and made a payment of $200,000 in exchange for the right to acquire certain shares of the Investee’s common stock and preferred stock. For the three months ended September 30, 2017, the Company did not record investment income from this investment.

The Company’s investments in unconsolidated entities consist of the following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Shaanxi Pharmaceutical Holding Group Longevity Pharmacy Co., Ltd. (Ankang Longevity Pharmacy) |  | $ | 2,921,271 |  |  | $ | 2,744,391 |
Shaanxi Pharmaceutical Sunsimiao Drugstores Ankang Chain Co., Ltd. |  |  | 644,916 |  |  |  | 611,228 |
Zhejiang Zhen’Ai Network Warehousing Services Co., Ltd. |  |  | 2,178,843 |  |  |  | 2,139,461 |
Original Lab Inc. |  |  | 200,000 |  |  |  | 200,000 |
Total |  | $ | 5,945,030 |  |  | $ | 5,695,080 |

Summarized financial information of unconsolidated entities is as follows:

|  | September 30, 2017 |  |  | June 30, 2017 |
Current assets |  | $ | 35,535,941 |  |  | $ | 32,880,168 |
Noncurrent assets |  |  | 264,785 |  |  |  | 281,162 |
Current liabilities |  |  | 28,538,267 |  |  |  | 26,328,322 |

|  | For the three months ended September 30, |
|  | 2017 |  |  | 2016 |
Net sales |  | $ | 7,445,561 |  |  | $ | 7,072,032 |
Gross profit |  |  | 969,677 |  |  |  | 895,484 |
Income from operations |  |  | 303,766 |  |  |  | 328,365 |
Net income |  |  | 302,975 |  |  |  | 328,941 |

NOTE 7 - DEPOSIT FOR BUSINESS ACQUISITION

On December 12, 2016, Tenet-Jove entered into a purchase agreement with Tianjin Tajite E-Commerce Co., Ltd. (“Tianjin Tajite”), an online e-commerce company based in Tianjin, China, specializing in distributing Luobuma related products and Japanese health products to the elderly, pursuant to which Tenet-Jove intends to acquire a 51% equity interest in Tianjin Tajite for cash consideration of RMB 14,000,000 (approximately $2.1 million). On December 25, 2016, the Company paid the full amount as the deposit to secure the deal. In May, 2017, the Company amended the agreement that requires that Tianjin Tajite to satisfy certain preconditions related to product introductions into China. On October 26, 2017, the Company has completed the acquisition for 51% of the shares in Tianjin Tajite.

| F-14 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 8 - PREPAID LEASES

One of the Company’s controlled subsidiaries, Zhisheng Group entered into several farmland lease contracts with farmer cooperatives to lease farmland in order to plant and grow organic vegetables, fruit and Chinese yew trees. The lease terms vary from 5 years to 24 years. The aggregate prepaid lease payments on these leases was approximately RMB 36.7 million (approximately $5.5 million). Zhisheng Group prepaid the entire required lease amounts plus transfer fees at the beginning of the lease.

These leases are accounted for as operating leases and will be amortized each year on a straight-line basis over the lease terms. The amortization expense is initially recorded as work in process in the inventory account during the growing period and then transferred to harvested crops costs at the time of harvest and then allocated to cost of sales when they are sold.

Future amortization expense will be recognizedas follows:

Twelve months ending September 30: |  |  |
2018 |  | $ | 474,550 |
2019 |  |  | 474,550 |
2020 |  |  | 388,398 |
2021 |  |  | 216,094 |
2022 |  |  | 216,094 |
Thereafter |  |  | 1,965,873 |
Total |  | $ | 3,735,559 |

NOTE 9 - SHORT-TERM LOANS

Short-term loans consist of the following:

Lender |  | September 30, 2017 |  |  | Maturity Date |  | Int. Rate/Year |
Agricultural Bank of China-b |  | $ | 300,530 |  |  | 2017-10-16 | * |  | 5.22 | %
Agricultural Bank of China-d |  |  | 1,202,120 |  |  | 2017-12-7 |  |  | 5.22 | %
Agricultural Bank of China-d |  |  | 300,530 |  |  | 2018-7-3 |  |  | 5.22 | %
Agricultural Bank of China-e |  |  | 450,795 |  |  | 2017-11-15 |  |  | 5.22 | %
Total |  | $ | 2,253,975 |  |  |  |  |  |  |

Lender |  | June 30, 2017 |  |  | Maturity Date |  | Int. Rate/Year |
Wanxiang Trust Co., Ltd-a |  | $ | 7,746 |  |  | 2017-9-9 | * |  | 13.48 | %
Agricultural Bank of China-b |  |  | 295,098 |  |  | 2017-10-16 | * |  | 5.22 | %
Agricultural Bank of China-c |  |  | 737,745 |  |  | 2017-8-17 | * |  | 5.66 | %
Agricultural Bank of China-d |  |  | 1,180,392 |  |  | 2017-12-7 |  |  | 5.22 | %
Agricultural Bank of China-e |  |  | 442,647 |  |  | 2017-11-15 |  |  | 5.22 | %
Total |  | $ | 2,663,628 |  |  |  |  |  |  |

| F-15 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

The loans outstanding were guaranteed by the following properties, entities or individuals:

a. Not collateralized or guaranteed.

b. Collateralized by the building owned by Xiaoyan Chen and Jing Chen, who are both related parties of the Company. Xiaoyan Chen is one of the shareholders of Ankang Longevity Group. Jing Chen is the sister of the Xiaoyan Chen but not a shareholder of Ankang Longevity Group.

c. Guaranteed by commercial credit guaranty companies unrelated to the Company.

d. Guaranteed by a commercial credit guaranty company, unrelated to the Company and also by Jiping Chen, a shareholder of the Company.

e. Guaranteed by a third-party company and also by Jiping Chen, a shareholder of the Company.

* The Company repaid the loans in full on maturity date.

The Company recorded interest expense of $36,028 and $39,303 for the three months ended September 30, 2017 and 2016, respectively. The annual weighted average interest rates are 5.38% and 5.48% for the three months ended September 30, 2017 and 2016, respectively.

NOTE 10 - RELATED PARTY TRANSACTIONS

DUE FROM RELATED PARTIES

The Company had previously made temporary advances to certain shareholders of the Company and to other entities that are either owned by family members of those shareholders or to other entities that the Company has investments in. Those advances are due on demand, non-interest bearing.

As of September 30, 2017 and June 30, 2017, the outstanding amounts due from related parties consist of the following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Yang Bin |  | $ | 150,265 |  |  | $ | 147,550 |
Zhang Xin |  |  | 93,164 |  |  |  | 91,480 |
Chang Song |  |  | 74,381 |  |  |  | 73,037 |
Zhang Xinyu |  |  | 62,572 |  |  |  | 61,441 |
Zhang Hua |  |  | 42,074 |  |  |  | 28,034 |
Beijing Huiyinansheng Asset Management Co., Ltd |  |  | 22,540 |  |  |  | 22,132 |
Zhang Yuying |  |  | - |  |  |  | 15,567 |
Wang Qiwei |  |  | 8,266 |  |  |  | 8,117 |
Tian Shuangpeng |  |  | 1,503 |  |  |  | 1,475 |
|  | $ | 454,765 |  |  | $ | 448,833 |

DUE TO RELATED PARTIES

As of September 30, 2017 and June 30, 2017, the Company had related party payables of $305,191 and $257,880, respectively, mainly due to the principal shareholders or certain relatives of the shareholders of the Company who lend funds for the Company’s operations. The payables are unsecured, non-interest bearing and due on demand.

| F-16 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

|  | September 30, 2017 |  |  | June 30, 2017 |
Wu Yang |  | $ | 96,245 |  |  | $ | 94,505 |
Wang Sai |  |  | 115,830 |  |  |  | 71,942 |
Zhao Min |  |  | 93,116 |  |  |  | 91,433 |
|  | $ | 305,191 |  |  | $ | 257,880 |

SALES TO RELATED PARTIES

For the three months ended September 30, 2017 and 2016, the Company recorded sales to Shaanxi Pharmaceutical Group, a related party , of $771,604 and $800,199, respectively. As of September 30, 2017 and June 30, 2017, the balance of accounts receivable due from Shaanxi Pharmaceutical Group was $1,790,094 and $2,205,453, respectively.

NOTE 11 - TAXES

| (a) | Corporate Income Taxes

The Company is subject to income taxes on an entity basis on income arising in or derived from the location in which each entity is domiciled.

Shineco is incorporated in the United States and has no operating activities. Tenet-Jove and its VIEs entities are governed by the Income Tax Laws of the PRC, and are currently subject to tax at a statutory rate of 25% on taxable income. Two VIE entities receive a full income tax exemption from the local tax authority of the PRC as agricultural enterprises as long as the favorable tax policy remains unchanged.

| i) | The components of the income tax expense are as follows:

|  | For the three months ended September 30, |
|  | 2017 |  |  | 2016 |
Current income tax provision |  | $ | 309,336 |  |  | $ | 205,519 |
Deferred income tax benefit |  |  | (26,479 | ) |  |  | (3,883 | )
Total |  | $ | 282,857 |  |  | $ | 201,636 |

| ii) | The following table summarizes deferred tax assets resulting from differences between the financial reporting basis and tax basis of assets and liabilities:

|  | September 30, 2017 |  |  | June 30, 2017 |
Allowance for doubtful accounts |  | $ | 28,055 |  |  | $ | 24,598 |
Inventory reserve |  |  | 236,622 |  |  |  | 209,236 |
Net operating loss carry-forwards |  |  | 113,941 |  |  |  | 111,882 |
Total |  |  | 378,618 |  |  |  | 345,716 |
Valuation allowance |  |  | (113,941 | ) |  |  | (111,882 | )
Deferred tax assets, net |  | $ | 264,677 |  |  | $ | 233,834 |

| F-17 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Movement of the valuation allowance:

|  | September 30, 2017 |  |  | June 30, 2017 |
Beginning balance |  | $ | 111,882 |  |  | $ | 114,122 |
Exchange difference |  |  | 2,059 |  |  |  | (2,240 | )
Ending balance |  | $ | 113,941 |  |  | $ | 111,882 |

(b) Value Added Tax

The Company is subject to a value added tax (“VAT”) for selling merchandise. The applicable VAT rate is 17% for products sold in the PRC. The amount of VAT liability is determined by applying the applicable tax rate to the invoiced amount of goods sold (output VAT) less VAT paid on purchases made with the relevant supporting invoices (input VAT). Under commercial practice in the PRC, the Company pays VAT based on tax invoices issued. The tax invoices may be issued subsequent to the date on which revenue is recognized, and there may be a considerable delay between the date on which the revenue is recognized and the date on which the tax invoice is issued.

In the event that the PRC tax authorities dispute the date on which revenue is recognized for tax purposes, the PRC tax office has the right to assess a penalty based on the amount of the taxes which are determined to be late or deficient, and will be expensed in the period if and when a determination is made by the tax authorities. There were no assessed penalties during the three months ended September 30, 2017 and 2017.

(c) Taxes Payable

Taxes payable consists of the following:

|  | September 30, 2017 |  |  | June 30, 2017 |
Income tax payable |  | $ | 1,605,869 |  |  | $ | 1,541,548 |
Value added tax payable |  |  | 55,118 |  |  |  | 60,685 |
Business tax and other taxes payable |  |  | 6,758 |  |  |  | 6,693 |
|  | $ | 1,667,745 |  |  | $ | 1,608,926 |

NOTE 12 – SHAREHOLDERS’ EQUITY

Initial Public Offering

On September 28, 2016, the Company completed its initial public offering of 1,713,190 shares of common stock at a price of $4.50 per share for gross proceeds of $7.7 million and net proceeds of approximately $5.4 million. The Company’s common shares began trading on September 28, 2016 on the NASDAQ Capital Market under the symbol “TYHT .”

| F-18 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

Statutory Reserve

The Company is required to make appropriations to reserve funds, comprising the statutory surplus reserve and discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”).

Appropriations to the statutory surplus reserve is required to be at least 10% of the after tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entities’ registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the Board of Directors. As of September 30, 2017 and June 30, 2017, the balance of the statutory reserve was $3,570,859 and $3,484,449, respectively.

NOTE 13 - CONCENTRATIONS AND RISKS

The Company maintains principally all bank accounts in the PRC for which there is no insurance. The cash balance held in the PRC bank accounts was $27,622,150 and $23,112,124 as of September 30, 2017 and June 30, 2017, respectively.

During the three months ended September 30, 2017 and 2016, almost 100% of the Company's assets were located in the PRC and 100% of the Company's revenues were derived from its subsidiaries and VIEs located in the PRC.

For the three months ended September 30, 2017, three customers accounted for approximately 22%, 12% and 10% of the Company’s total sales, respectively. At September 30, 2017, four customers accounted for approximately 69% of the Company’s accounts receivable. For the three months ended September 30, 2016, three customers accounted for approximately 38%, 11% and 11% of the Company’s total sales, respectively. At September 30, 2016, two customers accounted for approximately 72% of the Company’s accounts receivable.

For the three months ended September 30, 2017, five vendors accounted for approximately 19%, 13%, 12%, 11% and 11% of the Company’s total purchases, respectively. For the three months ended September 30, 2016, six vendors accounted for approximately 17%, 17%, 13%, 12%, 11% and 10% of the Company’s total purchases, respectively.

NOTE 14 - COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company leases nine main office spaces under non-cancelable operating lease agreements through December 10, 2020. The Company also leases farmland under a non-cancelable operating lease agreement through April 26, 2041. Most of those operating lease payments are scheduled on a quarterly basis. The future minimum rental payments are as follows:

Twelve months ending September 30: |  |  |
2018 |  | $ | 640,936 |
2019 |  |  | 449,057 |
2020 |  |  | 288,379 |
2021 |  |  | 222,137 |
2022 |  |  | 215,885 |
Thereafter |  |  | 4,011,857 |
Total |  | $ | 5,828,251 |

Rent expense totaled $128,456 and $99,839 for the three months ended September 30, 2017 and 2016, respectively.

| F-19 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

In addition, the Company sublets the above-mentioned farmland to a third party under a non-cancelable operating lease agreement through May 31, 2020. The future minimum sublease rental income to be received is as follows:

Twelve months ending September 30: |  |  |
2018 |  | $ | 209,888 |
2019 |  |  | 209,888 |
2020 |  |  | 143,923 |
Total |  | $ | 563,699 |

Sublease rental income totaled $53,971 and $53,998 for the three months ended September 30, 2017 and 2016, respectively.

Legal Contingencies

On May 16, 2017, Bonwick Capital Partners, LLC (“Plaintiff”) commenced a lawsuit (Case No. 1:17-cv-03681-PGG) against the Company in the United States District Court for the Southern District of New York. Plaintiff alleges that the Company entered into an agreement with Plaintiff (the “Agreement”), pursuant to which Plaintiff was to provide the Company with financial advisory services in connection with the Company’s initial public offering in the United States. Plaintiff alleges that the Company breached the Agreement and seeks money damages up to $6 million. The Company believes that these claims are without merit and intends to vigorously defend itself.

NOTE 15 - SEGMENT REPORTING

ASC 280, “Segment Reporting”, establishes standards for reporting information about operating segments on a basis consistent with the Group's internal organizational management structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Group's business segments.

The Company's chief operating decision maker has been identified as the Chief Executive Officer who reviews the financial information of separate operating segments when making decisions about allocating resources and assessing performance of the Group. Based on management's assessment, the Company has determined that it has three operating segments according to its major products and locations as follows:

Ø | Developing, manufacturing and distributing of specialized fabrics, textile products and other by-products derived from an indigenous Chinese plant called Apocynum Venetum, commonly known as “Bluish Dogbane” or known in Chinese as “Luobuma” (referred to herein as Luobuma):

The operating companies of this segment, namely Tenet-Jove and Tenet Huatai, specialize in Luobuma developing and manufacturing of relevant products.

This segment’s operations are focused in the north region of Mainland China, mostly carried out in Beijing and Tianjin City.

| Ø | Processing and distributing of traditional Chinese medicinal herbal products as well as other pharmaceutical products (“Herbal products”):

The operating companies of this segment, namely AnKang Longevity Group and its subsidiaries, process more than 600 kinds of Chinese medicinal herbal products with an established domestic sales and distribution network.

Ankang Longevity Group is also engaged in the retail pharmacy business and the operating revenue, which is not material, is also included in this segment.

| F-20 |

Shineco, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

| Ø | Planting, processing and distributing of green and organic agricultural produce as well as growing and cultivating of Chinese Yew trees (“Agricultural products”):

The operating companies of this segment, the Zhisheng Group, is engaged in the business of growing and distributing green and organic vegetables and fruits as well as providing logistics services for distributing agricultural products. This segment has been focusing its efforts on the growing and cultivating of Chinese yew trees (formally known as “taxus media”), a small evergreen tree whose branches can be used for the production of anti-cancer medications and the tree itself can be used as an ornamental indoor bonsai tree, which are known to have the effect of purifying air quality.

The operations of this segment are located in the East and North regions of Mainland China, mostly carried out in Shandong Province and in Beijing where the Zhisheng Group has newly developed over 100 acres of modern greenhouses for cultivating yew trees and other plants.

The following table presents summarized information by segment for the three months ended September 30, 2017:

|  | For the three months ended September 30, 2017 |
|  | Bluish |  |  | Herbal |  |  | Agricultural |  |  |  |
|  | dogbane |  |  | products |  |  | products |  |  | Total |
Segment revenue |  | $ | 1,046,297 |  |  | $ | 3,265,893 |  |  | $ | 3,497,304 |  |  | $ | 7,809,494 |
Cost of goods |  |  | 581,291 |  |  |  | 2,585,063 |  |  |  | 2,539,157 |  |  |  | 5,705,511 |
Business and sales related tax |  |  | 4,472 |  |  |  | 11,141 |  |  |  | - |  |  |  | 15,613 |
Gross profit |  |  | 460,534 |  |  |  | 669,689 |  |  |  | 958,147 |  |  |  | 2,088,370 |
Gross profit contribution % |  |  | 22.1 | % |  |  | 32.1 | % |  |  | 45.8 | % |  |  | 100.0 | %

The following table presents summarized information by segment for the three months ended September 30, 2016:

|  | For the three months ended September 30, 2016 |
|  | Bluish |  |  | Herbal |  |  | Agricultural |  |  |  |
|  | dogbane |  |  | products |  |  | products |  |  | Total |
Segment revenue |  | $ | 737,461 |  |  | $ | 3,180,371 |  |  | $ | 2,448,832 |  |  | $ | 6,366,664 |
Cost of goods |  |  | 367,220 |  |  |  | 2,437,713 |  |  |  | 1,631,239 |  |  |  | 4,436,172 |
Business and sales related tax |  |  | 3,604 |  |  |  | 11,941 |  |  |  | - |  |  |  | 15,545 |
Gross profit |  |  | 366,637 |  |  |  | 730,717 |  |  |  | 817,593 |  |  |  | 1,914,947 |
Gross profit contribution % |  |  | 19.1 | % |  |  | 38.2 | % |  |  | 42.7 | % |  |  | 100.0 | %

Total Assets as of

|  | September 30, 2017 |  |  | June 30, 2017 |
Bluish Dogbane or “Luobuma” |  | $ | 7,188,041 |  |  | $ | 6,983,551 |
Herbal products |  |  | 37,142,813 |  |  |  | 35,222,278 |
Agricultural products |  |  | 26,945,434 |  |  |  | 26,079,141 |
|  | $ | 71,276,288 |  |  | $ | 68,284,970 |

NOTE 16 – SUBSEQUENT EVENTS

On October 27, 2017, the Company, through its subsidiary Tianjin Tajit E-Commerce Ltd., obtained contractual rights to distribute branded products of Daiso Industries Co., Ltd.(“Daiso”), a large franchise of 100-yen shops founded in Japan, via JD.com (“JD”), the largest e-commerce company and largest retailer in China. On November 3, 2017, the Company further developed the cooperation with Daiso by entering into a supply and purchase agreement (the “Agreement”) for the purpose of establishing a continuous supply and sale of Daiso’s products in China. Pursuant to the Agreement, Shineco shall purchase Daiso Products in the amount of approximate RMB 20 million no later than December 31, 2017 and add orders as circumstance requires. The term of the Agreement is currently one year, and it extends for one additional year at each expiration date unless written notice of termination is given by either of the parties of the Agreement.

On November 1, 2017, the Company established an Apocynum Industrial Park in Xinjiang, China.

| F-21 |

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The following discussion and analysis of the results of our operations and financial condition for the three months ended September 30, 2017 and 2016 should be read in conjunction with our unaudited condensed consolidated financial statements, and the notes to those unaudited condensed consolidated financial statements that are included elsewhere in this Report and our annual report on Form 10-K for the twelve months ended June 30, 2017 and 2016, including the consolidated financial statements and notes thereto. All monetary figures are presented in U.S. dollars, unless otherwise indicated.

Forward-Looking Statements

The statements in this discussion that are not historical facts are “forward-looking statements.” The words “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” the negative forms thereof, or similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements are identified by those words or expressions. Forward-looking statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control. Actual results, performance or achievements may differ materially from those expressed or implied by forward-looking statements depending on a variety of important factors, including, but not limited to, weather, local, regional, national and global Luobuma and herbal medicines price fluctuations, availability of financing and interest rates, competition, changes in, or failure to comply with, government regulations, costs, uncertainties and other effects of legal and other administrative proceedings, and other risks and uncertainties. We are not undertaking to update or revise any forward-looking statement, whether as a result of new information, future events or circumstances or otherwise.

Business Overview

Shineco, Inc. (the “Company”, “we”, “us” and “our”) was incorporated in the State of Delaware on August 20, 1997. On December 30, 2004, the Company acquired all of the issued and outstanding shares of Beijing Tenet-Jove Technological Development Co., Ltd. (“Tenet-Jove”), a PRC company, in exchange for our restricted shares of common stock. Consequently, Tenet-Jove became our 100% owned subsidiary and its operating business became that of the Company. Tenet-Jove was incorporated on December 15, 2003 under the laws of China and was officially granted the status of a Wholly Foreign-Owned Entity (“WFOE”) by Chinese authorities on July 14, 2006. This transaction was accounted for as a recapitalization. Tenet-Jove owns a 90% interest of Tianjin Tenet Huatai Technological Development Co., Ltd. (“Tenet Huatai”).

| 4 |

On December 31, 2008, June 11, 2011 and May 24, 2012, Tenet-Jove entered into a series of contractual agreements with Ankang Longevity Pharmaceutical (Group) Co., Ltd. (“Ankang Longevity Group”), Yantai Zhisheng International Freight Forwarding Co., Ltd. (“Zhisheng Freight”), Yantai Zhisheng International Trade Co., Ltd. (“Zhisheng Trade”), Yantai Mouping District Zhisheng Agricultural Produce Cooperative (“Zhisheng Agricultural”) and Qingdao Zhihesheng Agricultural Produce Services., Ltd. (“Qingdao Zhihesheng”). On February 24, 2014, Tenet-Jove entered into the same series of contractual agreements with Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. (“Zhisheng Bio-Tech”), which was incorporated in 2014. Zhisheng Bio-Tech, Zhisheng Freight, Zhisheng Trade, Zhisheng Agricultural, and Qingdao Zhihesheng are collectively referred to herein as “Zhisheng Group.” The contractual agreements include an Executive Business Cooperation Agreement, Timely Reporting Agreement, Equity Interest Pledge Agreement and Executive Option Agreement.

Pursuant to these agreements, Tenet-Jove has the exclusive right to provide to Zhisheng Group and Ankang Longevity Group consulting services related to their business operations and management. All these contractual agreements obligate Tenet-Jove to absorb a majority of the risk of loss from the Zhisheng Group and Ankang Longevity Group’s activities and entitle Tenet-Jove to receive a majority of their residual returns. In essence, Tenet-Jove has gained effective control over the Zhisheng Group and Ankang Longevity Group. Based on these contractual arrangements, the Zhisheng Group and Ankang Longevity are treated as Variable Interest Entities (“VIEs”) under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 “Consolidation”. Accordingly, the accounts of these entities are consolidated with those of Tenet-Jove. We carry out all of our business in China through our PRC subsidiaries, our VIEs and their subsidiaries. Currently, we operate three main business segments: (i) Tenet-Jove is engaged in the manufacturing and selling of Bluish Dogbane and related products, also known in Chinese as “Luobuma,” including therapeutic clothing and textile products made from Luobuma; (ii) Zhisheng Group is engaged in the business of planting, processing and distributing of green agricultural produce as well as providing domestic and international logistic services for agricultural products (“Agricultural Products”); and, (iii) Ankang Longevity manufactures traditional Chinese medicinal herbal products as well as other retail pharmaceutical products. These different business activities and products can potentially be integrated and benefit from one and other.

On April 19, 2017, Tenet-Jove established Xinjiang Tiankunrunze Biological Engineering Co., Ltd. (“Tiankunrunze”) and continues to own 65% interest of Tiankunrunze. On April 28, 2017, Tiankunrunze established Xinjiang Tianzhuo Technology Development Co., Ltd. (“Tianzhuo”) with registered capital of RMB 10.0 million ($1,450,233). On May 22, 2017, Tiankunrunze established Xinjiang Tianhuihechuang Agriculture Development Co., Ltd. (“Tianhuihechuang”) with registered capital of RMB 10.0 million ($1,452,294). On May 23, 2017, Tiankunrunze established Xinjiang Tianxintongye Biotechnology Development Co., Ltd. (“Tianxintongye”) with registered capital of RMB 10.0 million ($1,451,615). Tianzhuo, Tianhuihechuang and Tianxintongye became subsidiaries of Tenet-Jove.

On May 2, 2017, the Company and its subsidiary Tiankunrunze entered into a Strategic Cooperation Agreement with Beijing Zhongke Biorefinery Engineering Technology Co., Ltd. (“Biorefinery”), a leading high-tech biomass refining company financially backed by the Chinese Academy of Sciences Institute of Process Engineering, to establish the Institute of Chinese Apocynum Industrial Technology Research (“ICAITR”). Pursuant to the Strategic Cooperation Agreement, the three parties agreed to establish the ICAITR and each will own 45%, 35% and 20% of the equity interests of ICAITR, respectively. Shineco and Tiankunrunze will invest RMB 5.0 million ($737,745) as the registered capital, and Biorefinery will invest technology such as the patent for “Steam Explosion Degumming,” as well as other resources.

| 5 |

On September 21, 2017, the Company, through its wholly owned subsidiary Tenet-Jove, entered into a Strategic Cooperation Agreement (the “Agreement”) with Mr. Jianjun Wang, who is experienced in apocynum planting, manufacturing and knowledgeable in apocynum market and administration procedures with relevant authorities in apocynum industry in China, to establish an Apocynum Industrial Park in Xinjiang, China. Pursuant to the Agreement entered into on September 21, 2017, both parties have agreed to establish a joint venture company, namely, Xinjiang Shineco Taihe Agriculture Technology Ltd. (“Xinjiang Taihe”) to hold and operate the Apocynum Industrial Park, with a total investment of RMB 50 million (approximately $7.57 million USD), of which the Company will invest RMB 47.5 million and Mr. Wang will invest RMB 2.5 million. Upon the closing of the Agreement, Shineco will own 95% of the equity interest of Xinjiang Taihe.

Factors Affecting Financial Performance

We believe that the following factors will affect our financial performance:

Increasing demand for our products - The increasing demand for our Chinese medicinal herbal products and our agricultural products will have a positive impact on our financial position. We plan to develop new products and expand our distribution network as well as to grow our business through possible mergers and acquisitions of similar or synergetic businesses, all aimed at increasing awareness of our brand, developing customer loyalty, meeting customer demands in various markets and providing solid foundations for our continuous growth. As of the date of this Report however, we do not have any agreements, undertakings or understandings to acquire any such entities and there can be no guarantee that we ever will.

Expansion of our sources of supply, production capacity and sales network - To meet the increasing demand for our products, we need to expand our sources of supply and production capacity. We plan to make capital improvements in our existing production facilities, which would improve both their efficiency and capacity. In the short-run, we intend to increase our investment in our reliable supply network, personnel training, information technology applications and logistic system upgrades. We also participate in two non-equity investment opportunities through a VIE, both of which we expect to provide us with new networks and platforms.

Maintaining effective control of our costs and expenses -Successful cost control depends upon our ability to obtain and maintain adequate material supplies as required by our operations at competitive prices. We will focus on improving our long-term cost control strategies including establishing long-term alliances with certain suppliers to ensure adequate supply is maintained. We will carry forward the economies of scale and advantages from our nationwide distribution network and diversified offerings. Moreover, we will step up our efforts in higher value added products of Luobuma by using an exclusive and patented technology, to optimize quality management, procurement processes and cost control, and give full play to the strong production capacity and trustworthy sales teams to maximize our profit and bring better long-term return for our shareholders.

Economic and Political Risks

Our operations are conducted primarily in the PRC. Accordingly, our business, financial conditions and results may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy.

Our operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks with, among others, the political, economic and legal environment and foreign currency exchange. Our Company’s results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversions, remittances abroad, and rates and methods of taxation, among other things.

| 6 |

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenue and expenses during the reporting period. Critical accounting policies are those accounting policies that may be material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance. While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies used in the preparation of our unaudited condensed consolidated financial statements require significant judgments and estimates. For additional information relating to these and other accounting policies, see Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Report.

Consolidation of Variable Interest Entities

In accordance with accounting standards regarding consolidation of VIEs, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision-making ability. All VIEs and their subsidiaries with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates required to be made by management include, but are not limited to, useful lives of property, plant, and equipment, and intangible assets, the recoverability of long-lived assets and the valuation of accounts receivable, accrued expenses and taxes payable and inventory reserves. Actual results could differ from those estimates.

Accounts Receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, the customers’ historical payment history, their current credit-worthiness and current economic trends. Accounts are written off against the allowance after efforts at collection prove unsuccessful.

| 7 |

Inventories

Inventories, which are stated at the lower of cost or current market value, consist of raw materials, work-in-progress, and finished goods related to the Company’s products. Cost is determined using the first in first out (“FIFO”) method. Market value is the lower of replacement cost or net realizable value. Agricultural products that the Company farms are recorded at cost, which includes direct costs such as seed selection, fertilizer, labor cost and contract fees that are spent in growing agricultural products on the leased farmland, and indirect costs which include amortization of prepayments of farmland leases and farmland development cost. All the costs are accumulated until the time of harvest and then allocated to the harvested crops costs when they are sold. The Company periodically evaluates its inventory and records an inventory reserve for certain inventories that may not be saleable or whose cost exceeds market prices.

Revenue Recognition

The Company recognizes revenue from sales of Luobuma products, Chinese medicinal herbal products and agricultural products, as well as providing logistic service and other processing services to external customers. The Company recognizes revenue when all of the following have occurred: (i) there is persuasive evidence of an arrangement with a customer, (ii) delivery has occurred or services have been rendered, (iii) the sales price is fixed or determinable, and (iv) the Company’s collection of such fees is reasonably assured. These criteria, as related to the Company’s revenue, are considered to have been met as follows:

Sales of products: the Company recognizes revenue from the sale of products when the goods are delivered and title to the goods passes to the customer provided that there are no uncertainties regarding customer acceptance; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability is deemed probable.

Revenue from the rendering of services: Revenue from international freight forwarding, domestic air and overland freight forwarding services is recognized upon the performance of services as stipulated in the underlying contract or when commodities are being released from the customer’s warehouse; the service price is fixed or determinable; and collectability is deemed probable.

Fair Value of Financial Instruments

The Company follows the provisions of ASC 820, “Fair Value Measurements and Disclosures.” ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

| 8 |

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying value of financial instruments included in current assets and liabilities approximate their fair values because of the short-term nature of these instruments.

Results of Operations for the Three Months Ended September 30, 2017 and 2016

Overview

The following table summarizes our results of operations for the three months ended September 30, 2017 and 2016:

|  | Three Months Ended September 30, |  |  | Variance |
|  | 2017 |  |  | 2016 |  |  | Amount |  |  | % |
Revenue |  | $ | 7,809,494 |  |  | $ | 6,366,664 |  |  | $ | 1,442,830 |  |  |  | 22.66 | %
Cost of revenue |  |  | 5,721,124 |  |  |  | 4,451,717 |  |  |  | 1,269,407 |  |  |  | 28.51 | %
Gross profit |  |  | 2,088,370 |  |  |  | 1,914,947 |  |  |  | 173,423 |  |  |  | 9.06 | %
General and administrative expenses |  |  | 835,551 |  |  |  | 473,764 |  |  |  | 361,787 |  |  |  | 76.36 | %
Selling expenses |  |  | 294,936 |  |  |  | 380,318 |  |  |  | (85,382 | ) |  |  | (22.45 | )%
Income from operations |  |  | 957,883 |  |  |  | 1,060,865 |  |  |  | (102,982 | ) |  |  | (9.71 | )%
Income from equity method investments |  |  | 148,458 |  |  |  | 161,182 |  |  |  | (12,724 | ) |  |  | (7.89 | )%
Purchase rebate income |  |  | 368,803 |  |  |  | 239,990 |  |  |  | 128,813 |  |  |  | 53.67 | %
Other income |  |  | 85,619 |  |  |  | 85,901 |  |  |  | (282 | ) |  |  | (0.33 | )%
Interest income (expense) |  |  | (19,185 | ) |  |  | 32,753 |  |  |  | (51,938 | ) |  |  | (158.57 | )%
Income before income tax provision |  |  | 1,541,578 |  |  |  | 1,580,691 |  |  |  | (39,113 | ) |  |  | (2.47 | )%
Provision for income taxes |  |  | 282,857 |  |  |  | 201,636 |  |  |  | 81,221 |  |  |  | 40.28 | %
Net income |  | $ | 1,258,721 |  |  | $ | 1,379,055 |  |  | $ | (120,334 | ) |  |  | (8.73 | )%
Comprehensive income attributable to Shineco Inc. |  | $ | 2,705,278 |  |  | $ | 1,155,748 |  |  | $ | 1,549,530 |  |  |  | 134.07 | %

| 9 |

Revenue

Currently, we have three types of revenue streams deriving from our three major business segments: First, developing, manufacturing and distributing specialized fabrics, textiles and other by-products derived from an indigenous Chinese plant Apocynum Venetum, known in Chinese as “Luobuma” or “Bluish Dogbane.” This segment is channeled through our directly owned subsidiary, Tenet-Jove. Second, processing and distributing traditional Chinese medicinal herbal products as well as other pharmaceutical products. This segment is conducted by our Ankang Longevity Group VIEs. And third, planting, processing and distributing green and organic agricultural produce as well as growing and cultivation of yew trees. This segment is conducted through our VIEs, the Zhisheng Group.

The following table sets forth the breakdown of our revenue for each of our three segments, for the three months ended September 30, 2017 and 2016, respectively:

|  | Three Months Ended September 30, |  |  | Variance |
|  | 2017 |  |  | % |  |  | 2016 |  |  | % |  |  | Amount |  |  | % |
Sales of Luobuma products |  | $ | 1,046,297 |  |  |  | 13.40 | % |  | $ | 737,461 |  |  |  | 11.59 | % |  | $ | 308,836 |  |  |  | 41.88 | %
Sales of Chinese medicinal herbal products |  |  | 3,265,893 |  |  |  | 41.82 | % |  |  | 3,180,371 |  |  |  | 49.95 | % |  |  | 85,522 |  |  |  | 2.69 | %
Sales of other agricultural products |  |  | 3,497,304 |  |  |  | 44.78 | % |  |  | 2,448,832 |  |  |  | 38.46 | % |  |  | 1,048,472 |  |  |  | 42.82 | %
Total Amount |  | $ | 7,809,494 |  |  |  | 100.00 | % |  | $ | 6,366,664 |  |  |  | 100.00 | % |  | $ | 1,442,830 |  |  |  | 22.66 | %

For the three months ended September 30, 2017 and 2016, revenue from sales of Luobuma products was $1,046,297 and $737,461, respectively, which represented an increase of $308,836 or 41.88%. The increase of revenue from this segment was due to increased sales volume of our health awareness related products. The sales volume increase was mainly due to the increase in our number of customers. The Company enhanced online sales promotions during the three months ended September 30, 2017.

For the three months ended September 30, 2017 and 2016, revenue from sales of Chinese medicinal herbal products was $3,265,893 and $3,180,371, respectively, representing a slight increase of $85,522 or 2.69%. The increase was mainly due to the fact that we fulfilled more sales orders from customers for the three months ended September 30, 2017 than the same period in 2016.

For the three months ended September 30, 2017 and 2016, revenue from sales of other agricultural products was $3,497,304 and $2,448,832, respectively, representing an increase of $1,048,472 or 42.82%. The increase was mainly due to the increase in sales volume of yew trees. In addition, in the second quarter of 2017, we developed a new business line of storage, which contributed approximately $0.4 million revenue in the three months ended September 30, 2017 compared to the corresponding period of 2016.

| 10 |

Cost of Revenue

The following table sets forth the breakdown of the Company’s cost of revenue for each of our three segments, for the three months ended September 30, 2017 and 2016, respectively:

|  | Three Months Ended September 30, |  |  | Variance |
|  | 2017 |  |  | % |  |  | 2016 |  |  | % |  |  | Amount |  |  | % |
Sales of Luobuma products |  | $ | 581,291 |  |  |  | 10.16 | % |  | $ | 367,220 |  |  |  | 8.25 | % |  | $ | 214,071 |  |  |  | 58.30 | %
Sales of Chinese medicinal herbal products |  |  | 2,585,063 |  |  |  | 45.18 | % |  |  | 2,437,713 |  |  |  | 54.76 | % |  |  | 147,350 |  |  |  | 6.04 | %
Sales of other agricultural products |  |  | 2,539,157 |  |  |  | 44.39 | % |  |  | 1,631,239 |  |  |  | 36.64 | % |  |  | 907,918 |  |  |  | 55.66 | %
Business and sales related tax |  |  | 15,613 |  |  |  | 0.27 | % |  |  | 15,545 |  |  |  | 0.35 | % |  |  | 68 |  |  |  | 0.44 | %
Total Amount |  | $ | 5,721,124 |  |  |  | 100.00 | % |  | $ | 4,451,717 |  |  |  | 100.00 | % |  | $ | 1,269,407 |  |  |  | 28.51 | %

For the three months ended September 30, 2017 and 2016, cost of revenue from sales of our Luobuma products was $581,291 and $367,220, respectively, representing an increase of $214,071 or 58.30%. The increase of cost of revenue was mainly due to increased sales volume of our health awareness related products. The percentage of the increase in cost of revenue was higher than the increase in sales during this period, primarily due to the higher raw material costs for the three months ended September 30, 2017 as compared to the corresponding period in 2016.

For the three months ended September 30, 2017 and 2016, cost of revenue from sales of Chinese medicinal herbal products was $2,585,063 and $2,437,713, respectively, representing an increase of $147,350 or 6.04%. The increase was mainly due to increased sales orders for the three months ended September 30, 2017 compared to the same period in 2016. The percentage of the increase in cost of revenue was higher than the increase in sales during this period, primarily due to the higher raw material and labor costs we incurred in the three months ended September 20, 2017 as compared with those in the corresponding period in 2016.

For the three months ended September 30, 2017 and 2016, cost of revenue from sales of other agricultural products was $2,539,157 and $1,631,239, respectively, representing an increase of $907,918 or 55.66%. The increase was mainly due to the increase in sales volume of yew trees. Since the second quarter of fiscal 2017, we developed a storage business line which has a relatively high cost compared with sales of our agricultural products, resulting in higher percentage of the increase in cost of revenue than sales during this period.

Gross Profit

The following table sets forth the breakdown of the Company’s gross profit for each of our three segments, for the three months ended September 30, 2017 and 2016, respectively:

|  | Three Months Ended September 30, |  |  | Variance |
|  | 2017 |  |  | % |  |  | 2016 |  |  | % |  |  | Amount |  |  | % |
Sales of Luobuma products |  | $ | 460,534 |  |  |  | 22.05 | % |  | $ | 366,637 |  |  |  | 19.15 | % |  | $ | 93,897 |  |  |  | 25.61 | %
Sales of Chinese medicinal herbal products |  |  | 669,689 |  |  |  | 32.07 | % |  |  | 730,717 |  |  |  | 38.16 | % |  |  | (61,028 | ) |  |  | (8.35 | )%
Sales of other agricultural products |  |  | 958,147 |  |  |  | 45.88 | % |  |  | 817,593 |  |  |  | 42.69 | % |  |  | 140,554 |  |  |  | 17.19 | %
Total Amount |  | $ | 2,088,370 |  |  |  | 100.00 | % |  | $ | 1,914,947 |  |  |  | 100.00 | % |  | $ | 173,423 |  |  |  | 9.06 | %

Gross profit from Luobuma product sales increased by $93,897 and gross profit contribution percentage increased by 25.61% for the three months ended September 30, 2017 as compared to the same period of 2016. The increase in gross profit was primarily due to increase in sales volume resulting from the sale of health products. The percentage of increase in gross profit was lower than the percentage of increase in sales mainly due to the higher raw material costs for the three months ended September 30, 2017 as compared to the corresponding period in 2016.

Gross profit from sales of Chinese medicinal herbal products decreased by $61,028 or 8.35% for the three months ended September 30, 2017 as compared to the same period of 2016. The decrease mainly resulted from higher raw material and labor costs we incurred in the three months ended September 20, 2017 as compared with those in the corresponding period in 2016.

| 11 |

Gross profit from sales of other agricultural products increased by $140,554 or 17.19% for the three months ended September 30, 2017 as compared to the same period of 2016. The increase was mainly due to the increase in sales volume of yew trees and increased storage business line with lower gross margin.

Expenses

The following table sets forth the breakdown of our operating expenses for the three months ended September 30, 2017 and 2016, respectively:

|  | Three Months Ended September 30, |  |  | Variance |
|  | 2017 |  |  | % |  |  | 2016 |  |  | % |  |  | Amount |  |  | % |
General and administrative expenses |  | $ | 835,551 |  |  |  | 73.91 | % |  | $ | 473,764 |  |  |  | 55.47 | % |  | $ | 361,787 |  |  |  | 76.36 | %
Selling expenses |  |  | 294,936 |  |  |  | 26.09 | % |  |  | 380,318 |  |  |  | 44.53 | % |  |  | (85,382 | ) |  |  | (22.45 | )%
Total Amount |  | $ | 1,130,487 |  |  |  | 100.00 | % |  | $ | 854,082 |  |  |  | 100.00 | % |  | $ | 276,405 |  |  |  | 32.36 | %

General and Administrative Expenses

For the three months ended September 30, 2017, our general and administrative expenses were $835,551, representing an increase of $361,787 or 76.36%, as compared to the same period of 2016. The increase was primarily due to the incorporation of Tiankunrunze in April 19, 2017 and increased professional service fees, such as attorney’s fees, consulting fees and auditing fees.

Selling Expenses

For the three months ended September 30, 2017, our selling and distribution expenses were $294,936, representing a decrease of $85,382, or 22.45%, as compared to the same period of 2016. The decrease was primarily due to decreased advertising expenses, salary expenses, and service fees of e-commerce websites, partially offset by increased promotion expenses during the three months ended September 30, 2017 compared to the same period of 2016.

Income from Equity Method Investments

We are 49% participants in two joint ventures with Shaanxi Pharmaceutical Group Pai’ang Medicine Co. Ltd. (“Shaanxi Pharmaceutical Group”): Shaanxi Pharmaceutical Sunsimiao Drugstores Ankang Retail Chain Co., Ltd. (“Sunsimiao Drugstores”), and Shaanxi Pharmaceutical Holding Group Longevity Pharmacy Co., Ltd. (“Shaanxi Longevity Pharmacy”). We recorded net income of $148,458 and $161,182 from these equity method investments for the three months ended September 30, 2017 and 2016, respectively. The decrease in net income was primarily due to lower net profit in the two joint ventures in the current period.

We invested RMB 14.5 million (approximately $2.2 million) into Tiancang Systematic Warehousing project (“Tiancang Project”) operated by Zhen’Ai Network. The Tiancang Project is currently operational. For the three months ended September 30, 2017 and 2016, we did not record investment income from Zhen’Ai Network.

On November 21, 2016, the Company (the “Investor”) entered into an agreement with Original Lab Inc., a California corporation (the “Investee”), pursuant to which the Investor made a payment of $200,000 to the Investee in exchange for the right to acquire certain shares of the Investee’s common stock and preferred stock. For the three months ended September 30, 2017, the Company did not record investment income from this investment.

| 12 |

Purchase Rebate Income

We are party to a supplemental agreement with Shaanxi Pharmaceutical Group. According to the supplemental agreement, the participants in the joint venture companies established by Shaanxi Pharmaceutical Group and Ankang Longevity Group are required to purchase certain raw materials and drug products exclusively from Shaanxi Pharmaceutical Group. In return, Shaanxi Pharmaceutical Group has agreed to compensate Ankang Longevity Group with a purchase rebate of 7% of the total purchases made from Shaanxi Pharmaceutical Group. For the three months ended September 30, 2017, total income of $368,803 was recognized by Ankang Longevity Group from this supplemental agreement, compared to $239,990 in the same period in 2016 due to the increase in purchases in the current period.

Interest Income (Expense), net

For the three months ended September 30, 2017, our net interest expense was $19,185 as compared to interest income of $32,753 in the same period of 2016. The significant decrease in net interest income was primarily due to decreased interest income on the loan to Xinyang Yifangyuan Garden Technology Co., Ltd. (“Xinyang Yifangyuan”). Xinyang Yifangyuan paid off the loan of RMB 3,000,000 in December, 2016. Interest income of nil and $56,248 was recognized on the loans for the three months ended September 30, 2017 and 2016, respectively.

Provision for Income Taxes

For the three months ended September 30, 2017 and 2016, the Company’s provision for income taxes increased by $81,221 or 40.28 % to $282,857 for the three months ended September 30, 2017 from $201,636 for the three months ended September 30, 2016. The increase in the Company’s provision for income taxes was primarily due to increased taxable income of Tenet-Jove and Ankang Longevity Group for the period indicated.

Net Income

Our net income decreased by $120,334 or 8.73% for the three months ended September 30, 2017 as compared to the same period of 2016. The decrease in net income was primarily a result of the increase in general and administrative expenses, partially offset by the increase in revenue.

Comprehensive Income

The comprehensive income was $2,728,131 for the three months ended September 30, 2017, an increase of $1,545,757 from comprehensive income of $1,182,374 for the three months ended September 30, 2016. After deduction of non-controlling interest, the comprehensive income attributable to the Company was $2,705,278 for the three months ended September 30, 2017, compared to comprehensive income of $1,155,748 for the three months ended September 30, 2016.

Liquidity and Capital Resources

We currently finance our business operations primarily through cash flows from operations and our initial public offering, as well as from short-term loans. Our current cash primarily consists of cash on hand and cash in bank, which is unrestricted as to withdrawal and use and is deposited with banks in China.

On September 28, 2016, we completed the initial public offering of 1,713,190 shares of the Company’s common stock at a price of $4.50 per share for gross proceeds of $7.7 million and net proceeds of approximately $5.4 million. We intend to use 54%, 16%, 25% and 5% of the proceeds received from our IPO for the expansion of a high-pressure steam degumming proceed project, development of Ziyang County, China Chinese herbal medicine farm, a processing plants project and development of e-commerce platform projects and working capital, respectively.

| 13 |

Management believes that our current cash, cash flows from current and future operations, and access to loans will be sufficient to meet our working capital needs for at least the next 12 months. We intend to continue to carefully execute our growth plans and manage market risk.

Treasury Policies

We have established treasury policies with the objectives of achieving effective control of treasury operations and of lowering cost of funds. Therefore, funding for all operations and foreign exchange exposure have been centrally reviewed and monitored from the top level. To manage our exposure to fluctuations in exchange rates and interest rates on specific transactions and foreign currency borrowings, currency structured instruments and other appropriate financial instruments will be used to hedge material exposure, if any.

Our policy precludes us from entering into any derivative contracts purely for speculative activities. Through our treasury policies, we aim to:

(a) Minimize interest risk

This is accomplished by loan re-financing and negotiation. We will continue to closely monitor the total loan portfolio and compare the loan margin spread under our existing agreements against the current borrowing interest rates under different currencies and new offers from banks.

(b) Minimize currency risk

In view of the current volatile currency market, we will closely monitor the foreign currency borrowings at the company level. As of September 30, 2017 and June 30, 2017, we do not engage in any foreign currency borrowings or loan contracts.

Working Capital

The following table provides the information about our working capital at September 30, 2017 and June 30, 2017:

|  | September 30, 2017 |  |  | June 30, 2017 |
Current Assets |  | $ | 47,370,175 |  |  | $ | 44,725,927 |
Current Liabilities |  |  | 5,294,235 |  |  |  | 5,031,048 |
Working Capital |  | $ | 42,075,940 |  |  | $ | 39,694,879 |

| 14 |

The working capital increased by $2,381,061 or 6.0% at September 30, 2017 from June 30, 2017, primarily as a result of an increase in cash due to better operating results during the three months ended September 30, 2017. We believe that we currently have sufficient working capital to run our business.

As of September 30, 2017 and June 30, 2017, the other major component of our working capital is accounts receivable.

The accounts receivable as of September 30, 2017 were $13,152,878, a decrease of approximately 9.17% from $14,480,004 as of June 30, 2017, mainly due to a decrease of revenue receivable from Qingdao Zhihesheng and Ankang Longevity Group. In January 2017, the Company entered into two accounts receivable repayment plans with two major customers, Qingdao Ship Owners Association and Shaanxi Pharmaceutical Group, who each agreed to pay RMB 2.0 million ($300,530 as of September 30, 2017) per month starting from March 2017, and the balance of accounts receivable from them as of December 31, 2016 will be paid off before December 31, 2017. As date of this Report, the account receivables from these two major customers were collected under the repayment plan. In the meanwhile, the Company continually made sales transactions with these two customers.

Capital Commitments and Contingencies

Capital commitments refer to the allocation of funds for the possible purchase in the near future for fixed assets or investment. Contingency refers to a condition that arises from past transactions or events, the outcome of which will be confirmed only by the occurrence or non-occurrence of uncertain futures events.

As of September 30, 2017 and June 30, 2017, we had no material capital commitments or contingent liabilities.

Cash Flows

The following table provides detailed information about our net cash flows for the three months ended September 30, 2017 and 2016.

|  | For the three months ended September 30, |
|  | 2017 |  |  | 2016 |
Net cash provided by operating activities |  | $ | 3,685,124 |  |  | $ | 415,509 |
Net cash provided by (used in) investing activities |  |  | 823,382 |  |  |  | (284 | )
Net cash provided by (used in) financing activities |  |  | (415,164 | ) |  |  | 6,330,556 |
Effect of exchange rate changes on cash |  |  | 481,047 |  |  |  | (85,654 | )
Net increase in cash |  |  | 4,574,389 |  |  |  | 6,660,127 |
Cash, beginning of period |  |  | 23,154,551 |  |  |  | 22,009,374 |
Cash, end of period |  | $ | 27,728,940 |  |  | $ | 28,669,501 |

Operating Activities

Net cash provided by operating activities during the three months ended September 30, 2017 was approximately $3.7 million, consisting of net income of $1.3 million and net changes in our operating assets and liabilities, which mainly included a decrease in accounts receivable of $1.6 million and an increase in advances from customers of $0.7 million. Net cash provided by operating activities during the three months ended September 30, 2016 was approximately $0.4 million, consisting of net income of $1.4 million, net changes in our operating assets and liabilities, which mainly included an increase in accounts receivable of $1.4 million, reduction in inventory of $0.6 million and repayment in advances to suppliers of $0.4 million.

| 15 |

Investing Activities

For the three months ended September 30, 2017, net cash provided by investing activities amounted to $823,382 as compared to net cash used in investing activities of $284 for the same period of 2016. The increase in net cash provided by investing activities was primarily due to collections on loans to third parties of $0.8 million during the three months ended September 30, 2017.

Financing Activities

For the three months ended September 30, 2017, net cash used in financing activities amounted to $0.4 million, as opposed to net cash provided by financing activities of $6.3 million for the same period of 2016. The decrease of $6.7 million in net cash provided by financing activities was primarily due to net repayment of short-term loans of $0.5 million for the three months ended September 30, 2017 and net proceeds from our initial public offering of $5.4 million for the three months ended September 30, 2016.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a small reporting company, we are not required to provide the information required by this item.

ITEM 4. CONTROLS AND PROCEDURES

| (a) | Evaluation of Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company’s disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Report due to following material weaknesses:

· The Company does not have U.S. GAAP full-time qualified personnel in the accounting department to monitor the recording of the daily transactions; and,

· Lack of segregation of duties for accounting personnel who prepared and reviewed the journal entries.

In order to address the above material weaknesses, our management plans to take the following steps:

· Recruiting sufficient qualified professionals with appropriate levels of knowledge of U.S. GAAP and experience to assist in reviewing and resolving accounting issues in routine or complex transactions. To mitigate the reporting risks, we engaged an outside professional consulting firm to supplement our efforts to improve our internal control over financial reporting;

· Improving the communication between management, our board of directors and the Chief Financial Officer; and

· Obtaining proper approval for other significant and non-routine transactions from the Board of Directors.

| 16 |

The Company believes the foregoing measures will remediate the identified material weaknesses in future periods. The Company is committed to monitoring the effectiveness of these measures and making any changes that are necessary and appropriate.

| (b) | Changes in Internal Control over Financial Reporting

Other than described above, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during our first fiscal quarter of 2018. Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect all misstatements. Further, because of changes in conditions, effectiveness of internal controls over financial reporting may vary over time. Our system contains self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

Other than ordinary routine litigation (of which we are not currently involved), we know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation, and there are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our company except as set forth below:

On May 16, 2017, Bonwick Capital Partners, LLC (“Plaintiff”) commenced a lawsuit (Case No. 1:17-cv-03681-PGG) against the Company in the United States District Court for the Southern District of New York. Plaintiff alleges that the Company entered into an agreement with Plaintiff (the “Agreement”), pursuant to which Plaintiff was to provide the Company with financial advisory services in connection with the Company’s initial public offering in the United States. Plaintiff alleges that the Company breached the Agreement and seeks money damages up to $6 million. The Company believes that these claims are without merit and intends to vigorously defend itself.

ITEM 1A. RISK FACTORS.

As a smaller reporting company, we are not required to provide the information otherwise required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

| 17 |

ITEM 6. EXHIBITS

Exhibit Number |  | Description
3.1 |  | Certificate of Incorporation of Shineco, Inc. (1)
3.2 |  | Amended and Restated Bylaws of Shineco, Inc. (1)
4.1 |  | Specimen Common Stock Share Certificate (2)
31.1 |  | Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
31.2 |  | Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
32.1 |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
32.2 |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101. INS |  | XBRL Instance Document *
101. SCH |  | XBRL Taxonomy Extension Schema Document *
101. CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document*
101. DEF |  | XBRL Taxonomy Extension Definition Linkbase Document*
101. LAB |  | XBRL Taxonomy Extension Label Linkbase Document*
101. PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document*

* Filed herewith.

| (1) | Incorporated by reference to the Amendment No. 1 to Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on July 1, 2015.

| (2) | Incorporated by reference to the Amendment No. 5 to Registration Statement on Form S-1 filed by the Company with the SEC on January 27, 2016.

| 18 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

| SHINECO, INC.
Dated: November 14, 2017 | By: | /s/ Yuying Zhang
|  | Yuying Zhang
|  | Chief Executive Officer
|  | (Principal Executive Officer)
Dated: November 14, 2017 | By: | /s/ Sai (Sam) Wang
|  | Sai (Sam) Wang
|  | Chief Financial Officer
|  | (Principal Financial and Accounting Officer)

| 19 |